MRI and Biomarker Monitoring for Head and Neck Cancer

Overseen by Clifton D. Fuller

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial aims to find ways to predict how tumors in the head and neck respond to treatment. The goal is to improve understanding of tumor responses and plan better treatments.

Research Team

Clifton D. Fuller

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for adults with certain head and neck cancers who haven't had distant metastases or previous radiation treatments in the affected area. They should be fit enough for curative radiotherapy, not pregnant, and able to undergo MRI scans without contraindications like metal implants or severe kidney issues.

Inclusion Criteria

I have not had surgery on my head or neck cancer, except for biopsy.

I can take care of myself and am up and about more than half of my waking hours.

I am of child-bearing age and my pregnancy test is negative.

Exclusion Criteria

I had radiation for head or neck cancer in the last 5 years.

Pregnant or breast-feeding females

Contraindications to magnetic resonance (MR) imaging

Treatment Details

Interventions

• Biospecimen Collection (Procedure)
• Magnetic Resonance Imaging (Procedure)
• Quality-of-Life Assessment (Other)

Trial Overview Researchers are testing if additional MRIs and blood biomarker analysis can predict tumor changes during radiation therapy. Participants will have extra scans and blood tests beyond standard care to see if these methods improve understanding of treatment response.

Participant Groups

Group I: Diagnostic (MRI, blood sample collection) Experimental Treatment 4 Interventions

Patients undergo MRI scans and collection of blood samples for biomarker testing pre-radiation therapy, weekly during radiation therapy, and at 2-3 months post-radiation therapy.

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials

3,107

Recruited

1,813,000+

Dr. Peter WT Pisters

M.D. Anderson Cancer Center

Chief Executive Officer since 2017

MD from University of Western Ontario

Dr. Jeffrey E. Lee

M.D. Anderson Cancer Center

Chief Medical Officer

MD from Stanford University School of Medicine

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Dr. Douglas R. Lowy

National Cancer Institute (NCI)

Chief Executive Officer since 2023

MD from New York University School of Medicine

Dr. Monica Bertagnolli

National Cancer Institute (NCI)

Chief Medical Officer since 2022

MD from Harvard Medical School